A Mechanism-Based Classification of Dermatologic Reactions to Biologic Agents Used in the Treatment of Cutaneous Disease: Part 2

被引：12
作者：
Bremmer, Matthew [1 ]
Deng, April [1 ]
Gaspari, Anthony A. [1 ]
机构：
[1] Univ Maryland, Dept Dermatol, Baltimore, MD 21201 USA
来源：
DERMATITIS | 2009年 / 20卷 / 05期
关键词：
NECROSIS-FACTOR-ALPHA; SEVERE PLAQUE PSORIASIS; RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; DOUBLE-BLIND; PALMOPLANTAR PUSTULOSIS; INFUSION REACTIONS; EFALIZUMAB THERAPY; INFLIXIMAB THERAPY; CLINICAL-RESPONSE;
D O I：
10.2310/6620.2009.09010b
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Biologic therapies are an efficacious new method of controlling a number of chronic conditions. Data regarding these medications continues to emerge, giving clinicians a greater understanding of their side effects profiles. The biologic agents used in dermatology, particularly the tumor necrosis factor-a inhibitors, have a number of varied dermatologic side effects. In this two-part article, we perform a review of literature regarding cutaneous side effects of infliximab, etanercept, adalimumab, rituximab, efalizurnab, and alefacept. In this second part, we discuss injection site reactions, infusion reactions, vasculitis, drug-induced lupus erythematosus, psoriasiform lesions, rebound phenomenon, eczema, atopic dermatitis, and hypersensitivity reactions
引用
收藏
页码：243 / 256
页数：14
相关论文
共 94 条
  • [1] Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-α inhibitors
    Aeberli, D
    Seitz, M
    Jüni, P
    Villiger, PM
    [J]. RHEUMATOLOGY, 2005, 44 (02) : 172 - 175
  • [2] Allen KP, 2005, COMPARATIVE MED, V55, P377
  • [3] Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-α blockade
    Arbach, O
    Gross, WL
    Gause, A
    [J]. IMMUNOBIOLOGY, 2002, 206 (05) : 496 - 501
  • [4] Skin reaction to adalimumab
    Beuthien, W
    Mellinghoff, HU
    von Kempis, J
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (05): : 1690 - 1692
  • [5] Etanercept-induced subacute cutaneous lupus erythematosus
    Bleumink, GS
    ter Borg, EJ
    Ramselaar, CG
    Stricker, BHC
    [J]. RHEUMATOLOGY, 2001, 40 (11) : 1317 - 1319
  • [6] Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
    Byrd, JC
    Murphy, T
    Howard, RS
    Lucas, MS
    Goodrich, A
    Park, K
    Pearson, M
    Waselenko, JK
    Ling, G
    Grever, MR
    Grillo-Lopez, AJ
    Rosenberg, J
    Kunkel, L
    Flinn, IW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) : 2153 - 2164
  • [7] Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonists
    Campi, Paolo
    Benucci, Maurizio
    Manfredi, Mariangela
    Demoly, Pascal
    [J]. CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 7 (05) : 393 - 403
  • [8] Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis
    Carlson, E
    Rothfield, N
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (04): : 1165 - 1166
  • [9] Chan Joanna L, 2004, J Drugs Dermatol, V3, P315
  • [10] Cheifetz A, 2005, MT SINAI J MED, V72, P250
12345678910